Transforming life for people living with Parkinson’s and other CNS disorders

Transforming life for people living with Parkinson’s and other CNS disorders

LATEST PRESS RELEASES
OCTOBER 8, 2024 / REGULATORY

IRLAB receives milestone payment of USD 2.5 million in conjunction with first dosing in a Phase I study with IRL757 in healthy older adults

Gothenburg, Sweden, October 8, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that dosing has been initiated in a Phase I clinical study of the drug candidate IRL757 in healthy adults aged 65 and older. This is the second clinical study with IRL757 and the first study under the collaboration framework with the McQuade Center (MSRD) a member of the global Otsuka family of pharmaceutical companies and will grant IRLAB a milestone payment of USD 2.5 million.

Read More >

Watch IRLAB’s
Capital Markets Day 2023!

IRLAB A
12.3
SEK
TODAY
0.82 %
TODAY SEK
0.10 SEK
16:00:00
2024-10-15
More share info >

ISP – The proprietary technology platform

IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

IRLAB’s clinical phase II candidates

Mesdopetam (IRL790)

In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.  

Pirepemat (IRL752)

In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.

LATEST PRESENTATION
SEPTEMBER 17, 2024

Q&A with Kristina Torfgård, CEO, at “Investing in Life Science 2024”

Kristina Torfgård, CEO, interviewed at “Investing in Life Science 2024”, an event hosted by BioStock and VatorSecurities, held on September 12, 2024. In Swedish only.

Read More >